Abstract: A cathode active material for a lithium secondary battery includes a lithium metal oxide particle and a thio-based compound formed on at least portion of a surface of the lithium metal oxide particle. The thio-based compound has a double bond that contains a sulfur atom. Chemical stability of the lithium metal oxide particle may be improved and surface residues may be reduced by the thio-based compound.

Abstract: Provided are a nitrogen-containing ring compound of the following Chemical Formula 1: and a color conversion film, a backlight unit and a display device including the same.

Abstract: The present invention relates to: a negative electrode active material including silicon-based composite particles containing SiOx (0<x<2) and a MgSiO3 phase, wherein the MgSiO3 phase includes a first MgSiO3 phase having an enstatite structure and a second MgSiO3 phase having a clinoenstatite structure at a weight ratio of 1:1 to 1:5; a negative electrode including the same; and a secondary battery including the negative electrode.

Abstract: A cathode active material for a lithium secondary battery includes a lithium metal oxide particle and a thio-based compound formed on at least portion of a surface of the lithium metal oxide particle. The thio-based compound has a double bond that contains a sulfur atom. Chemical stability of the lithium metal oxide particle may be improved and surface residues may be reduced by the thio-based compound.

Abstract: The present invention relates to a pharmaceutical composition comprising a novel compound as an active ingredient for prevention or treatment of transplant rejection. The novel compound SD911 of the present invention was identified to repress the migration of immune cells, increase the engraftment and viability of a grafted tissue, and regulate immune cells. In addition, it was found in a kidney transplantation model that the compound restrained human PBMC from suppressing the engraftment and damaging renal tissues and downregulated the expression of the inflammatory cytokine IL-17, with the consequent effective prevention and treatment of transplant rejection.

Abstract: Provided are a method of depositing a thin film and a method of manufacturing a semiconductor device using the same, and the method of depositing a thin film uses a substrate processing apparatus including a chamber, a substrate support on which a substrate is mounted, a gas supply unit, and a power supply unit that supplies high-frequency and low-frequency power to the chamber, and includes: a step of mounting, on the substrate support, the substrate including a lower thin film deposited under the condition of a process temperature in a low temperature range; a step of depositing an upper thin film on the lower thin film under the condition of the process temperature in the low temperature range; and a step of treating a surface of the upper thin film under the condition of the process temperature in the low temperature range.

Abstract: A blankmask for EUV lithography includes a substrate, a reflective layer, a capping layer, and a phase shift layer. The phase shift layer is made of a material containing ruthenium (Ru) and chromium (Cr), and a total content of ruthenium (Ru) and chromium (Cr) is 50 to 100 at %. The phase shift layer may further contain boron (B) or nitrogen (N). The phase shift layer of the present invention has a high relative reflectance (relative reflectance with respect to a reflectance of the reflective layer under the phase shift layer) with respect to a tantalum (Ta)-based phase shift layer and has a phase shift amount of 170 to 230°. It is possible to obtain excellent resolution when finally manufacturing a pattern of 7 nm or less by using a photomask manufactured using such a blankmask.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A polarizing plate and an optical display including the same are provided. A polarizing plate includes: a polarizer; and a first protective layer and a second protective layer sequentially stacked on a surface of the polarizer, and the second protective layer includes a positive C retardation layer, the positive C retardation layer having a thickness of about 10 ?m or less, an index of refraction of about 1.50 to about 1.55, and a glass transition temperature (Tg) of about 150° C. to about 250° C.

Abstract: Provided are a curcumin nanoparticle complex having a modified particle surface and a method for preparing same. A curcumin nanoparticle complex includes curcumin and phospholipids and has a particle size of less than 1000 nm. A first coating layer containing a cationic material and/or a second coating layer containing an anionic material can be further added.

Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of preparing tagatose using the same.

Abstract: Provided are an optical display device module and an optical display device including same, the optical display device module comprising an optical display device panel, and a first polarizing plate arranged on at least one surface of the optical display device panel, wherein the first polarizing plate includes a first polarizer and a first phase difference layer arranged between the first polarizer and the optical display device panel, the first phase difference layer includes at least a positive C layer, the optical display device panel includes a second phase difference layer therein, and the second phase difference layer and the first phase difference layer satisfy formula 1 and formula 2.

Abstract: According to one embodiment, An apparatus for preprocessing a security log includes a field divider configured to divide a character string of a security log into a plurality of fields on the basis of a structure of the security log, an ASCII code converter configured to convert a character string included in each of the plurality of divided fields into ASCII codes, and a vector data generator configured to generate vector data for each of the plurality of divided fields using the converted ASCII codes.

Abstract: The present disclosure relates to bacteriophage ?CJ28 (KCCM11466P) and a composition containing the same as an active ingredient. Further, the present disclosure relates to a method for preventing and/or treating infective diseases caused by enterotoxic Escherichia coli (ETEC) of animals excluding humans by using the composition. A bacteriophage ?CJ28 (KCCM11466P) has a specific ability to kill enterotoxigenic Escherichia coli.

Abstract: Provided are a tagatose-bisphosphate aldolase variant having tagatose conversion activity, and a method of preparing tagatose using the same.

Abstract: There is provided a method for producing calcium carbonate by utilizing seawater and calcinated shells, and calcium carbonate and a calcium agent produced thereby. The method for producing calcium carbonate includes: eluting calcium by mixing calcinated shells, seawater, and sugar; and generating calcium carbonate by injecting carbon dioxide into the calcium eluate generated in the eluting calcium. The calcium agent includes vaterite-type calcium carbonate.